|
| Primary information |
|---|
| ID | 10701 |
| Therapeutic ID | Th1160 |
| Protein Name | Satumomab Pendetide |
| Sequence | >Th1160_Satumomab_Pendetide
QVQLQQSDAELVKPGASVKISCKASGYTFTDHAIHWAKQKPEQGLEWIGYISPGNDDIKYNEKFKGKATLTADKSSSTAYMQLNSLTSEDSAVYFCKRSYYGHWGQGTTLTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSR
|
| Molecular Weight | 141478.9 |
| Chemical Formula | C6268H9708N1666O1971S48 |
| Isoelectric Point | 7.02 |
| Hydrophobicity | -0.427 |
| Melting point | 61 (FAB fr |
| Half-life | 0.80 hours(Mammalian reticulocytes) |
| Description | Tumor associated glycoprotein (TAG) 72 (B72.3) monoclonal antibody conjugated with Indium 111 for radioimaging colon tumors. Satumomab Pendetide (trade name: OncoScint) is no longer commercially available. |
| Indication/Disease | For diagnosis of extrahepatic malignant cancers |
| Pharmacodynamics | Binds to the tumor associated glycoprotein 72 antigen, which is a cell surface protein generally over-expressed in colorectal cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of TAG-72 expressing cells and tumors |
| Mechanism of Action | Satumomab Pendetide is a monoclonal antibody which is attached to the chelator pentetic acid (DTPA) linked to the tripeptide glycine (G) – L-tyrosine (Y) – L-lysine (K), which chelates Indium 111. Satumomab pendetide binds selectively to cell-surface TAG-72 expressed on colorectal tumors. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| NA |
| Clearance | NA |
| Categories | Diagnostic Agents |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Tumor-associated glycoprotein 72 (TAG-72) |
| Brand Name | OncoScint |
| Company | Cytogen Corp, Lonza Biologics |
| Brand Description | Cytogen Corp, Lonza Biologics |
| Prescribed For | Extrahepatic malignant disease (diagnosis)â€â€Indium In 111 satumomab pendetide is indicated for use in immunoscintigraphy in patients with known colorectal or ovarian cancer. |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | Intravenous Injection |
| Recommended Dosage | Estimated dose- 0.32 mSv/MBq |
| Contraindication | NA |
| Side Effects | Chillls, Diarrhea, Dizziness, Flushing of Skin, Allergic reactions, confusion, hypertension, Skin rashes, hypothermia, nausea, headache. |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |